You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Engineering stem cells to make mucopolysaccharidosis IIIB

    SBC: Phoenix Nest Inc.            Topic: 107

    DESCRIPTION provided by applicant Sanfilippo disease type B also called mucopolysaccharidosis type III or MPS III is a devastating neuro degenerative genetic disorder of childhood that is fatal There is no cure or effective treatment MPS IIIB is caused by the lack of a lysosomal enzyme called NAGLU alpha N acetylglucosaminidase that is required to degrade heparan sulfate glycosaminoglyca ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Expanding teleconsent capabilities to improve clinical research recruitment

    SBC: Doxy.me Inc.            Topic: NLM

    Lack of recruitment of qualified research participants into clinical trials remains to be one of the most important issues in clinical research Studies often struggle to meet recruitment goals on time resulting in costly time extensions underpowered results and in some cases early termination Many reasons attribute to suboptimal recruitment including the challenges related to informing and c ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. improving Cas9 mediated homologous recombination in pluripotent stem cells

    SBC: APPLIED STEMCELL, INC.            Topic: 200

    DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications

    SBC: GENECAPTURE, INC.            Topic: CBD15C001

    The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula

    STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense
  5. Innovative High Energy Density Storage in Nano Vacuum Tubes (NVTs) Designed for Small Leakage Curren

    SBC: APPLIED MATERIAL SYSTEMS ENGINEERING, INC.            Topic: T302

    NASA's various Space Mission Directorate seek to develop technology to fulfill the technology gap and to enable missions with the unique high energy density charge storage technology. The overall goal of this STTR proposal is attempt to develop the novel energy storage technology to enable and enhance the capabilities of future NASA missions. The unique set of requirements for the power systems fo ...

    STTR Phase I 2016 National Aeronautics and Space Administration
  6. In-Situ Spectroscopic Europa Explorer (ISEE)

    SBC: Honeybee Robotics, Ltd.            Topic: T803

    The US congress has instructed NASA to include a lander component in the next Europa mission. The mission has a target launch date of 2022, and its primary goal will be to search Europa?s icy surface for evidence of life that may persist within the ice shell or subsurface ocean. The Europa lander study specifically recommends a combination of a mass spectrometer and a Raman spectrometer to investi ...

    STTR Phase I 2016 National Aeronautics and Space Administration
  7. Integrated Optical Transmitter for Space Based Applications

    SBC: FREEDOM PHOTONICS LLC            Topic: T802

    The objective of this program is to develop, demonstrate and implement an integrated optical transmitter for RZ-DPSK modulation for integration into modems for the international space station (ISS). Conventional optical transmitters are based on commercially available discrete components. These have several fiber interconnects which leads to increased optical loss, reduced reliability in a space e ...

    STTR Phase I 2016 National Aeronautics and Space Administration
  8. Jamboxx: Interactive Respiratory Therapy through Music and Gaming

    SBC: My Music Machines Inc.            Topic: NHLBI

    DESCRIPTION provided by applicant The goal of this project is to develop a novel device for respiratory therapy that uses interactive gaming and music to encourage patient compliance In order to maintain pulmonary health many post operative surgery patients as well as people with quadriplegia and other spinal cord injuries high level motor neuron diseases such as amyotrophic lateral sclerosi ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Low Mass/Power Sensor Suite for Spacesuits

    SBC: SEACOAST SCIENCE, INC.            Topic: T601

    To provide additional telemetry and data for long-term mission, the composition of internal atmosphere of spacesuits must be determined. Specifically, the unambiguous detection and quantification of carbon dioxide is crucial for mission completion. Detection of other gasses (ammonia, oxygen) is also necessary for a complete sensor suite. Seacoast Science and Case Western Reserve University pro ...

    STTR Phase I 2016 National Aeronautics and Space Administration
  10. Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: NCI

    PARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA wild type cancers and to increase chemo radiosensitivity in these malignancies BRCA proteins are essential components ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government